|
maraviroc |
|
Prescribing Information |
| Direct Links to CCR5 Receptor Blocker Info | |
| Key Points | |
| Generic | Brand |
| maraviroc | Selzentry |
|
Maraviroc = Selzentry |
|||
| Forms Available | 150 and 300 mg tablets | ||
| Dosing |
150 mg twice daily
With CYP3A inhibitors: protease inhibitors except for tipranavir/ritonavir delavirdine ketoconazole, itraconazole, clarithromycin other strong CYP3A inhibitors (e.g., nefazadone, telithromycin) |
300 mg twice daily Other concomitant medications, including tipranavir/ritonavir, nevirapine, all NRTIs and enfuvirtide |
600 mg twice daily With CYP3A inducers (without a strong inhibitor) efavirenz rifampin carbemazepine, phenobarbital, phenytoin |
| Adverse Effects |
Maraviroc is an alpha-blocker with some antihypertensive
and orthostatic hypotension effects. Hepatotoxicity is rare, but possibly severe. |
||
| Interactions | See dosing above | ||
| Suggested lab follow-up |
Tropism assay must be performed prior to prescribing this medication, and
the result must indicated the absence of any CXCR4 (X4) virus. Routine virologic and safety monitoring should be performed during the administration of this medication. |
||
| Warning |
Hepatotoxicity:
if elevated liver enzymes are noted in association with
signs or symptoms of hepatitis, rash or other systemic symptoms,
discontinuation should be considered Cardiovascular events: there is possible association of maraviroc therapy with cardiac ischemia or infarction (1.3% vs none in placebo recipients) Orthostatic hypotension: caution should be advised when administering maraviroc to a patient with a history of orthostatic hypotension or to a patient taking antihypertensive medication |
||
| Complete prescribing information | Full prescribing information | ||
| Click HERE for Antiretroviral Therapy Summary and Recommendations |
| Links to Antiretroviral Sections |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddI | d4T | 3TC | ABC | FTC | TDF ||| Coformulation NRTI: Combivir | Trizivir | Epzicom | Truvada |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine | etravirine | rilpivirine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Co-receptor Inhibitors |
| maraviroc |
| Fusion Inhibitors |
| enfuvirtide |
| Integrase Inhibitors |
| raltegravir | elvitegravir |
| Antiretroviral Metabolic Inhibitors |
| cobicistat | ritonavir |
| Coformulations |
| Atripla (efavirenz/tenofovir/emtricitabine) | Complera (rilpivirine/tenofovir/emtricitabine) | Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) |
Updated 1/14/2013